What do systematic reviews say?

Loratadine 10 mg vs placebo (2‐week intervention)

Loratadine 10 mg/d showed no clear difference in secondary outcome 1. Physician‐assessed clinical signs Number for… compared with placebo (2‐week intervention) (low certainty).

• Oral H1 antihistamines as ‘add‐on’ therapy to topical treatment for eczema 2019 · Cochrane Headline outcomes only
  RR 2.04 [0.99, 4.2]
  1 study · 73 participants
  Low

Loratadine 10 mg vs placebo (2‐week intervention)

The review found no eligible studies for this question.

• Oral H1 antihistamines as ‘add‐on’ therapy to topical treatment for eczema 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Loratadine 10 mg vs placebo (2‐week intervention)

The review found no eligible studies for this question.

• Oral H1 antihistamines as ‘add‐on’ therapy to topical treatment for eczema 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Desloratadine 5 to 20 mg vs placebo

• H1‐antihistamines for chronic spontaneous urticaria 2014 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 46 participants
  Low

Desloratadine 5 to 20 mg vs placebo

• H1‐antihistamines for chronic spontaneous urticaria 2014 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 46 participants
  Low

Desloratadine 5 to 20 mg vs placebo

• H1‐antihistamines for chronic spontaneous urticaria 2014 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 80 participants
  Low

Desloratadine 5 to 20 mg vs placebo

Desloratadine 5 to 20 mg showed no clear difference in adverse effects leading to withdrawal: intermediate‐term duration of… compared with placebo (low certainty).

• H1‐antihistamines for chronic spontaneous urticaria 2014 · Cochrane Headline outcomes only
  RR 1.46 [0.42, 5.1]
  3 studies · 466 participants
  Low